Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY

3

Scope of the analysis

3

Datamonitor insight into the hospital antibacterial market

5

Across the seven major markets the hospital antibacterial market is currently valued at $6.4 billion, representing approximately 30% of total antibacterial sales. Of these sales, $1.2 billion (25%) are attributable to the treatment of respiratory tract infections, a figure that will rise to $2.0 billion (28%) by 2008 (CAGR 2002-2008 6.2%);

6

Increasing drug resistance in the hospital environment creates demand for novel more effective drug classes. However, restrictions on the use of such specialist products might equate to lower overall hospital sales. Datamonitor estimates that sales of Pfizer's Zyvox and Monarch's Synercid across the seven major markets reached only $133m and $51m, in 2002.

7

The responsibility, care and treatment of hospital patients is increasingly being shared between varieties of health professionals. As a result, companies marketing antibacterials may need to re-evaluate promotional strategy to incorporate a selection of physicians, pharmacists and microbiologists, while also taking into account regional and sector variations.

8

Historically, portfolio success within the hospital antibacterial sector has been achieved with one or two broad-spectrum products. Current drivers may increase the incentive to develop portfolios of multiple narrow spectrum products. In particular, smaller companies with expertise in target driven research and development may benefit from the reduced costs associated with smaller clinical trials.

10

Summary

12

Key metrics

13

TABLE OF CONTENTS

14

CHAPTER 2 HOSPITAL MARKET CONDITIONS

22

Introduction

22

Hospital-treated infections - patient composition

23

Hospital-acquired infections

23

Community-acquired infections treated in the hospital

27

Hospital units

28

Emergency room

29

Specialist wards

29

Drug resistance

30

Resistance control measures

33

The MRSA challenge

34

Infection control

34

Cost containment

39

Generic competition

44

CHAPTER 3 DRIVERS OF PRESCRIPTION CHOICE

47

Decision makers

48

Hospital physicians

48

Interactions between decision makers

51

Laboratory staff

52

Pharmacists

53

Interaction in the prescribing process

54

Regulation and guidance

56

Licensed indications

57

Treatment guidelines

60

Resistance issues

62

Off-label use

64

Regulatory control

67

Product characteristics

68

Targeted versus broad

69

Cost of therapy

71

Generic versus brand

74

Promotional information

79

CHAPTER 4 MARKET ANALYSIS

82

Introduction

82

Global market overview

83

Product analyses

85

Drivers of product switching

86

Product profiles

88

CHAPTER 5 STRATEGIC FOCUS

116

Introduction

116

Product costs and pricing

117

Cost containment and pharmacoeconomics

117

Cost of therapy

118

Reimbursement & formulary inclusion

128

Product characteristics

135

Resistance issues

135

Product attributes

141

Product positioning

143

Product promotion and marketing

146

Portfolio composition

152

Broad versus narrow spectrum

152

Portfolio focus versus diversification

154

Contributing experts

166

List of tables

167

List of figures

168

Bibliography

171

Physician research methodology

176

Physician Sample breakdown

176

US

176

Japan

177

France

177

Germany

178

Italy

178

Spain

179

UK

179

Key Opinion Leader Interview - US 1

180

Key Opinion Leader Interview - US 2

192

Key Opinion Leader Interview - US 3

197

Key Opinion Leader Interview - US 4

203

Key Opinion Leader Interview - US 5

210

Key Opinion Leader Interview - Germany 1

221

Key Opinion Leader Interview - Germany 2

228

Key Opinion Leader Interview - Germany 3

233

Key Opinion Leader Interview - UK 1

238

Key Opinion Leader Interview - UK 2

243

Key Opinion Leader Interviews - Italy 1

252

Key Opinion Leader Interview - France 1

260

Key Opinion Leader Interview - France 2

268

Key Opinion Leader Interviews - France 3

276

Key Opinion Leader Interview - Spain 1

285

Key Opinion Leader Interviews - Pharmacist (UK) 1

293

Key Opinion Leader Interviews - Pharmacist (US) 2

300

SECTION 1:

307

SECTION 2:

309

Section 3:

312

About Datamonitor

325

About Datamonitor Healthcare

325

Datamonitor Healthcare's research and analysis methodologies

326

Datamonitor Healthcare's therapy area capabilities

326

About the infectious disease analysis team

327

Datamonitor Healthcare's Consulting expertise

328

Key therapy team members

329

Disclaimer

331

List of Tables

Table 1: Hospital antibacterial sales by site of infection, 2002 & 2008

13

Table 2: Changing susceptibility of bacterial pathogens to key antibiotics, 1994-2000

31

Table 3: Percentage of nosocomial pathogens resistant to key hospital antibacterials

32

Table 4: Key patent expiries in antibacterials to 2007

46

Table 5: Indications by site of infection

57

Table 6: Indications by pathogens for the 10 products included in this study

59

Table 7: Price per gram of selected hospital antibacterials in the UK

118

Table 8: Cost of treatment with Cipro IV and oral Cipro in the UK

120

Table 9: Ontario Drug Benefit (ODB) formulary: major listing changes effective March 2001

132

Table 10: Leading companies and their marketed hospital antibacterial portfolios

153

Table 11: Product use by site of infection in the US (%)

156

Table 12: Product use by site of infection in Japan (%)

156

Table 13: Product use by site of infection in Germany (%)

157

Table 14: Product use by site of infection in France (%)

157

Table 15: Product use by site of infection in Italy (%)

158

Table 16: Product use by site of infection in Spain (%)

158

Table 17: Product use by site of infection in the UK (%)

159

Table 18: BTS treatment guidelines for community-acquired pneumonia in adults in the UK

160

Table 19: ERS treatment guidelines for community-acquired pneumonia in adults in the EU

161

Table 20: IDSA guidelines for the empiric treatment of CAP in adults

162

Table 21: Overall cost of BTS recommended CAP treatment regimes in the UK

163

Table 22: Overall cost of ERS recommended CAP treatment regimes in the EU

165

Table 23: Cost per gram of selected antibacterial products

165

Table 24: US physician sample breakdown, 2002

176

Table 25: Japan physician sample breakdown, 2002

177

Table 26: France physician sample breakdown, 2002

177

Table 27: Germany physician sample breakdown, 2002

178

Table 28: Italy physician sample breakdown, 2002

178

Table 29: Spain physician sample breakdown, 2002

179

Table 30: UK physician sample breakdown, 2002

179

List of Figures

Figure 1: Clinical and commercial drivers of broad versus narrow spectrum antibacterial therapy

12

Figure 2: Hospital antibacterial sales by region and key products, 2002

13

Figure 3: Treatment dynamics for bacterial infections

23

Figure 4: Changes in incidence of nosocomial infection

24

Figure 5: Mean additional hospital costs associated with nosocomial infections in the UK, by site of infection

25

Figure 6: Mean additional hospital costs associated with nosocomial infections in the UK, by admission specialty

26

Figure 7: Hospital treatment of community-acquired infections

27

Figure 8: Level of implementation of infection control measures across the seven major markets, 2003

37

Figure 9: Perceived effectiveness of infection control measures across the seven major markets, 2003

38

Figure 10: Total expenditure on healthcare per capita in the seven major markets (US$/PPP*), 1995-2001

39

Figure 11: Pharmaceutical expenditure as a proportion of total healthcare costs across the seven major markets, 1995-2001

40

Figure 12: Expenditure on in-patient care across the seven major markets (% of total healthcare spend), 1995-2001

41

Figure 13: Number of acute care beds across the seven major markets (per 1,000 population), 1995-2001

42

Figure 14: Impact of cost pressures on antibacterial prescription decisions across the seven major markets, 2003

43

Figure 15: Impact of cost pressures on antibacterial prescription decisions across hospital wards, 2003

44

Figure 16: Physician perception of availability of generic equivalents across the seven major markets

45

Figure 17: Interaction between hospital staff in the antibacterial prescription process

55

Figure 18: UK treatment guidelines hierarchy

61

Figure 19: The percentage product use for non-approved indications in the seven major markets

65

Figure 20: Factors driving prescription choice across the seven major markets, 2003

68

Figure 21: Changing antibiotic treatment paradigms in the seriously ill

70

Figure 22: Most physicians would select potent broad spectrum therapy where patients are high risk

71

Figure 23: Physician awareness of the relative costs of different antibacterial classes across the seven major markets, 2003

72

Figure 24: Average price per gram of leading product in each class across the seven major markets, 2003

73

Figure 25: Personnel determining the generic/brand prescription decision

75

Figure 26: Geographical variation in personnel determining generic/brand decisions.

76

Figure 27: Variation in personnel determining generic/brand decisions, across hospital wards.

77

Figure 28: Factors affecting the generic/brand prescription choice across the seven major markets

78

Figure 29: Impact of promotional information on prescription choice across the seven major markets

79

Figure 30: Impact of promotional information on prescription choice of 10 key hospital antibacterials

80

Figure 31: Total hospital antibacterial sales for 10 key products by site of infection in the seven markets, 2002

83

Figure 32: Total hospital antibacterial sales by site of infection and by country in the seven markets, 2002

85

Figure 33: Importance of efficacy on prescription decisions across the seven major markets, 2003

86

Figure 34: Factors driving physician switching across the seven major markets, 2003

87

Figure 35: Rocephin use by site of infection across the seven major markets (%)

89

Figure 36: Rocephin sales by site of infection in the seven markets, 2002

90

Figure 37: Fortum use by site of infection across the seven major markets (%)

92

Figure 38: Fortum sales by site of infection in the seven markets, 2002

93

Figure 39: Cipro use by site of infection across the seven major markets (%)

95

Figure 40: Cipro sales by site of infection in the seven markets, 2002

96

Figure 41: Levaquin use by site of infection across the seven major markets (%)

98

Figure 42: Levaquin sales by site of infection in the seven markets, 2002

99

Figure 43: Ketek use by site of infection in Italy and Spain (%)

100

Figure 44: Ketek sales by site of infection in the seven markets, 2002

101

Figure 45: Augmentin use by site of infection across the seven major markets (%)

103

Figure 46: Augmentin sales by site of infection in the seven markets, 2002

104

Figure 47: Primaxin use by site of infection across the seven major markets (%)

106

Figure 48: Primaxin sales by site of infection in the seven markets, 2002

107

Figure 49: Vancocin use by site of infection across the seven major markets (%)

108

Figure 50: Vancocin sales by site of infection in the seven markets, 2002

109

Figure 51: Zyvox use by site of infection in the UK, the US and Italy (%)

111

Figure 52: Zyvox sales by site of infection in the seven markets, 2002

112

Figure 53: Synercid use by site of infection in France, Italy and Germany (%)

113

Figure 54: Synercid sales by site of infection in the seven markets, 2002

114

Figure 55: Cost per gram of selected antibacterial products used in the treatment of CAP

122

Figure 56: Minimum and maximum costs incurred in the treatment of non-severe CAP in the hospital as recommended by national guidelines

123

Figure 57: Minimum and maximum costs incurred in the treatment of severe CAP in the hospital as recommended by national guidelines

124

Figure 58: CAP decision tree

126

Figure 59: IV/oral step down treatment for CAP

127

Figure 60: Factors in the antibacterial reimbursement process

129

Figure 61: Typical antibacterial prescription process for restricted products

136

Figure 62: Factors driving use of broad and narrow spectrum therapies

138

Figure 63: The impact of resistance on physician prescription decisions

140

Figure 64: Differences in patient and product requirements in hospital wards

146

Figure 65: Physician perception of how to improve marketing campaigns across the seven major markets

147

Figure 66: Physician perception of how to improve marketing campaigns across different hospital units

149

Figure 67: Information networks associated with the treatment of bacterial infections

151

Figure 68: Datamonitor's Healthcare Consultancy

328

Figure 69: Datamonitor Healthcare's Therapeutic Consulting capabilities

329